deltatrials
Unknown PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT03090659

LCAR-B38M Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma (LEGEND-2)

A Clinical Study of Legend Biotech BCMA-chimeric Antigen Receptor Technology in Treating Relapsed/Refractory (R/R) Multiple Myeloma Patients

Sponsor: Jiangsu Provincial People's Hospital

Conditions Refractory or Relapsed Multiple Myeloma
Interventions LCAR-B38M CAR-T cell injection
Updated 15 times since 2017 Last updated: Jun 8, 2023 Started: Oct 2, 2015 Primary completion: Dec 31, 2023 Completion: Dec 31, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03090659, this PHASE1/PHASE2 trial focuses on Refractory or Relapsed Multiple Myeloma and remains ongoing. Sponsored by Jiangsu Provincial People's Hospital, it has been updated 15 times since 2015, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~May 2017 – ~Aug 2017 · 3 months · monthly snapshot~Aug 2017 – ~Feb 2018 · 6 months · monthly snapshot~Feb 2018 – ~Jun 2018 · 4 months · monthly snapshot~Jun 2018 – ~Sep 2019 · 15 months · monthly snapshot~Sep 2019 – ~Nov 2019 · 2 months · monthly snapshot~Nov 2019 – ~Aug 2020 · 9 months · monthly snapshot~Aug 2020 – ~Jan 2021 · 5 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Oct 2021 · 7 months · monthly snapshot~Oct 2021 – ~Mar 2023 · 17 months · monthly snapshot~Mar 2023 – ~Jul 2023 · 4 months · monthly snapshot~Jul 2023 – ~Jul 2024 · 12 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Jun 2025 · 9 months · monthly snapshot~Jun 2025 – present · 13 months · monthly snapshot

Change History

15 versions recorded

  1. Jun 2025 — Present [monthly]

    Unknown PHASE1/PHASE2

    Status: Active Not Recruiting → Unknown

  2. Sep 2024 — Jun 2025 [monthly]

    Active Not Recruiting PHASE1/PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  4. Jul 2023 — Jul 2024 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Unknown Status → Active Not Recruiting

  5. Mar 2023 — Jul 2023 [monthly]

    Unknown Status PHASE1_PHASE2

    Status: Active Not Recruiting → Unknown Status

▶ Show 10 earlier versions

  1. Oct 2021 — Mar 2023 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  2. Mar 2021 — Oct 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  3. Jan 2021 — Mar 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  4. Aug 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Enrolling By Invitation → Active Not Recruiting

  5. Nov 2019 — Aug 2020 [monthly]

    Enrolling By Invitation PHASE1_PHASE2

  6. Sep 2019 — Nov 2019 [monthly]

    Enrolling By Invitation PHASE1_PHASE2

  7. Jun 2018 — Sep 2019 [monthly]

    Enrolling By Invitation PHASE1_PHASE2

  8. Feb 2018 — Jun 2018 [monthly]

    Enrolling By Invitation PHASE1_PHASE2

  9. Aug 2017 — Feb 2018 [monthly]

    Enrolling By Invitation PHASE1_PHASE2

    Status: Active Not Recruiting → Enrolling By Invitation

  10. May 2017 — Aug 2017 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    First recorded

Oct 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Jiangsu Provincial People's Hospital
  • Nanjing Legend Biotech Co.
  • Ruijin Hospital
  • Second Affiliated Hospital of Xi'an Jiaotong University
  • Shanghai Changzheng Hospital
Data source: Nanjing Legend Biotech Co.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.